![Hans-Georg Capraro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Dr. Hans-Georg Capraro is Head-Medicinal Chemistry at Oncalis AG.
Dr. Capraro was previously employed as a Principal by Ciba-Geigy AG and a Principal by Novartis AG.
He received his doctorate degree from the Swiss Federal Institute of Technology.
Antiguos cargos conocidos de Hans-Georg Capraro.
Empresas | Cargo | Fin |
---|---|---|
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Corporate Officer/Principal | 14/12/2011 |
NOVARTIS AG | Corporate Officer/Principal | - |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | - |
Formación de Hans-Georg Capraro.
Swiss Federal Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NOVARTIS AG | Health Technology |
Empresas privadas | 2 |
---|---|
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Health Technology |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Hans-Georg Capraro